- Home
- HGV vs KNSA Comparison
HGV vs KNSA Comparison
Compare HGV & KNSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HGV | KNSA |
|---|---|---|
| Founded | 1992 | 2015 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Hotels/Resorts | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.2B | 4.9B |
| IPO Year | 2017 | 2018 |
Fundamental Metrics
Financial Performance| Metric | HGV | KNSA |
|---|---|---|
| Price | $44.59 | $77.75 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 8 | 7 |
| Target Price | $52.13 | ★ $60.86 |
| AVG Volume (30 Days) | ★ 1.1M | 679.1K |
| Earning Date | 04-30-2026 | 04-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 97.78 | ★ 225.00 |
| EPS | ★ 0.95 | 0.27 |
| Revenue | ★ $5,047,000,000.00 | $677,564,000.00 |
| Revenue This Year | $25.30 | $37.48 |
| Revenue Next Year | $1.98 | $17.87 |
| P/E Ratio | ★ $47.26 | $288.67 |
| Revenue Growth | 1.33 | ★ 60.09 |
| 52 Week Low | $36.79 | $32.89 |
| 52 Week High | $55.40 | $82.94 |
Technical Indicators
Market Signals| Indicator | HGV | KNSA |
|---|---|---|
| Relative Strength Index (RSI) | 40.52 | 64.75 |
| Support Level | $43.58 | $40.06 |
| Resistance Level | $49.22 | $82.94 |
| Average True Range (ATR) | 1.89 | 3.94 |
| MACD | -0.35 | -0.01 |
| Stochastic Oscillator | 18.66 | 73.90 |
Price Performance
Historical ComparisonAbout HGV Hilton Grand Vacations Inc.
Hilton Grand Vacations Inc is a timeshare company engaged in developing, marketing, selling, managing, and operating timeshare resorts and timeshare plans under the Hilton Grand Vacations brand. The company operates in two segments: Real estate sales and financing, and Resort operations and club management. The Real estate sales and financing segment generates revenue from VOI sales and consumer financing, including interest income from loans to members. The Resort operations and club management segment generates revenue from resort management services, club membership fees, and rental of available inventory. The majority of the company's revenue is earned through the Real estate sales and financing segment.
About KNSA Kiniksa Pharmaceuticals Ltd.
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating cardiovascular diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and Vixarelimab. Geographically, the company earns maximum revenue from United States.